CEPHALON COMPLETES FINANCING TRIPLE PLAY IN 1993 -- PUBLIC OFFERING, PRIVATE PLACEMENT AND JOINT VENTURE; GENERIC STOCKS COUNTER BIOTECH BLUES
Executive Summary
Cephalon was a rare hit among biotech companies on Wall Street in 1993, helped by clinical progress on its Lou Gehrig's disease therapy and the financial equivalent of a triple play: a public offering in April, a collaborative agreement with SmithKline Beecham in June and a private placement in August.